Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 1471 to 1485 of 7959 results

  1. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    8 August 2018
    View recommendations

    Sections for TA537

  2. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA428

  3. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA404

  4. Baricitinib for moderate to severe rheumatoid arthritis (TA466)

    Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    9 August 2017
    View recommendations

    Sections for TA466

  5. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA575

  6. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    24 April 2019
    View recommendations

    Sections for TA577

  7. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    15 May 2019
    View recommendations

    Sections for TA580

  8. Cochlear implants for children and adults with severe to profound deafness (TA566)

    Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.

    Technology appraisal guidance
    Published
    7 March 2019
    View recommendations

    Sections for TA566

  9. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)

    Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.

    Technology appraisal guidance
    Published
    20 March 2019
    View recommendations

    Sections for TA571

  10. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    27 March 2019
    View recommendations

    Sections for TA572

  11. Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA574

  12. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA584

  13. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

    Technology appraisal guidance
    Last updated
    3 September 2019
    View recommendations

    Sections for TA565

  14. Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

    NICE is unable to make a recommendation about the use in the NHS of abatacept (Orencia) for treating psoriatic arthritis after DMARDs. This is because Bristol–Myers Squibb Pharmaceuticals Ltd did not provide an evidence submission.

    Technology appraisal guidance
    Published
    13 March 2019

    Sections for TA568

  15. Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

    NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. This is because Merck Sharp & Dohme UK Ltd did not provide an evidence submission

    Technology appraisal guidance
    Published
    20 March 2019

    Sections for TA570